Moleculin says Annamycin preclinical data show CD8+ T cell — mediated activity in pancreatic cancer models

Moleculin Biotech disclosed new preclinical pancreatic cancer data on Annamycin, presented at the AACR Conference on Pancreatic Cancer. Findings suggest the drug’s antitumor effect is partly driven by CD8+ T cells, indicating potential to make “cold” tumors more immune-responsive. The results support a possible combination strategy with immunotherapies, a key strategic angle in a disease where checkpoint inhibitors have struggled. Annamycin’s lead clinical focus remains the MIRACLE trial in relapsed or refractory AML; the pancreatic work is not in clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via (Ref. ID: 202609251305PRIMZONEFULLFEED9833773) on September 25, 2026, and is solely responsible for the information contained therein. (C)